-
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Friday, May 20, 2022 - 8:20am | 1228Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Recommends COVID-19 Boosters For Kids Ages 5-11 The U.S. Centers for Disease Control and Prevention recommended the COVID-19 vaccine booster for children ages 5 to 11 years after at...
-
CDC Recommends Pfizer/BioNTech COVID-19 Booster Shots For Kids Aged 5-11 Years
Friday, May 20, 2022 - 7:43am | 332The Centers for Disease Control and Prevention recommended that children ages 5 to 11 receive the newly authorized COVID-19 booster shot from Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX). Following the recommendation, many of the nation's doctors,...
-
Pfizer, NIH Mulling Study For Longer Paxlovid Course To Combat Reinfections
Thursday, May 19, 2022 - 3:44pm | 310The U.S. National Institutes of Health and Pfizer Inc (NYSE: PFE) are discussing testing a longer course of COVID-19 antiviral treatment Paxlovid, required to prevent reinfections, White House Chief Medical Officer Anthony Fauci said. "We're going to be planning what...
-
Read Why Pfizer Is Limiting Supply Of Paxlovid For Combination Studies: Bloomberg
Thursday, May 19, 2022 - 3:41pm | 296Amid rising concerns over the potential development of resistance to Pfizer Inc's (NYSE: PFE) COVID-19 pill Paxlovid, the company has declined to supply researchers with the antiviral for use in combination studies, according to a Bloomberg report. Researchers say that...
-
Immunome Shares Rise After Publishing Positive COVID-19 Antibody Cocktail Data
Thursday, May 19, 2022 - 3:27pm | 285Immunome Inc (NASDAQ: IMNM) shares are trading higher after it published data demonstrating that its COVID-19 antibody cocktail, IMM-BCP-01, potently cleared the omicron variant (BA.1) when tested in vivo in hamsters. Additional in vitro testing of a SARS-CoV-2 pseudovirus...
-
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
Thursday, May 19, 2022 - 8:01am | 1245Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Enanta's RSV Candidate Fails In Low-Risk Patient Population Enanta Pharmaceuticals Inc's (NASDAQ: ENTA) EDP-938 failed to reduce the total symptom score compared to...
-
The Daily Biotech Pulse: Pfizer/BioNTech's COVID-19 Booster For Kids, Moderna Starts First African Trial Of mRNA HIV Vaccine, Tonix Extends COVID-19 Antiviral Research Pact
Wednesday, May 18, 2022 - 10:15am | 1319Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus FDA Gives Green Signal To Pfizer/BioNTech's COVID-19 Booster For Kids 5-11 Years The FDA has authorized a booster shot of Pfizer Inc (NYSE: PFE) and BioNTech SE's...
-
Moderna's Chairman Defends Executive Hiring Process After Firing New CFO In Just One Day
Wednesday, May 18, 2022 - 7:52am | 367Moderna Inc’s (NASDAQ: MRNA) chairman comes forward with a determined defense of the board’s executive hiring process after being forced to fire its new chief financial officer just a day after taking charge. Afeyan said the executive search company contracted by Moderna was also...
-
FDA Declines Emergency Use Request For An Antidepressant As COVID-19 Treatment
Tuesday, May 17, 2022 - 3:54pm | 290The FDA has decided not to authorize fluvoxamine, an antidepressant, to treat COVID-19. The agency that data has not shown the drug to be an effective therapeutic for fighting the virus. "Based on the review of available scientific evidence, the FDA has determined that the data are...
-
AstraZeneca In-Licenses New Suite Of COVID-19 Antibody Candidate(s)
Tuesday, May 17, 2022 - 3:50pm | 320AstraZeneca plc (NASDAQ: AZN) moved to bolster its COVID-19 portfolio of antibodies with a $157 million licensing deal for experimental therapies developed by newly-launched UK-based biotech, RQ Biotechnology Ltd. In addition to the initial sum, AstraZeneca will pay possible...
-
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Tuesday, May 17, 2022 - 9:04am | 1795Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA May Authorize Pfizer-BioNTech's COVID-19 Booster For 5-11 Year Kids Soon: NYT The FDA is expected to authorize a booster shot of Pfizer Inc (NYSE: PFE)/BioNTech SE's (...
-
FDA Gives Nod To First Nonprescription COVID-19 Test That Also Detects Flu, RSV
Tuesday, May 17, 2022 - 7:29am | 274The FDA has authorized the first nonprescription test to detect Covid-19, influenza, and respiratory syncytial virus (RSV). The test, called the Labcorp Seasonal Respiratory Virus RT-PCR DTC Test, was developed by Laboratory Corp of America Holdings (NYSE: LH). It can be sold...
-
FDA May Authorize Pfizer-BioNTech's COVID-19 Booster For 5-11 Year Kids Soon: NYT
Tuesday, May 17, 2022 - 7:26am | 358The FDA is expected to authorize a booster shot of Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) COVID-19 vaccine for children aged 5 to 11 probably by today, the New York Times reported, citing people familiar with the matter. The companies submitted an...
-
EU Says Final Decision Yet To Be Taken On Terminating Valneva COVID-19 Vaccine Deal
Monday, May 16, 2022 - 2:15pm | 264The European Commission said that no final decision had been made about the possible termination of a contract with Valneva SE (NASDAQ: VALN) to supply its COVID-19 vaccine to the European Union. Earlier today, Valneva said it received a notice of intent from the Commission to...
-
Why Valneva's Shares Are Plunging Today Premarket
Monday, May 16, 2022 - 9:08am | 450Valneva SE (NASDAQ: VALN) warned it might have to reconsider its FY22 financial guidance after the European Commission informed the company of its intent to terminate an advance purchase agreement (APA) for its VLA2001 COVID-19 candidate vaccine. In November, the company signed the...